AFT Pharmaceuticals Limited (AFP.AX)
- Previous Close
2.3700 - Open
2.5400 - Bid 2.3700 x --
- Ask 2.5500 x --
- Day's Range
2.5400 - 2.5500 - 52 Week Range
2.1500 - 3.1600 - Volume
5,132 - Avg. Volume
1,064 - Market Cap (intraday)
267.408M - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
25.50 - EPS (TTM)
0.1000 - Earnings Date May 22, 2025
- Forward Dividend & Yield 0.01 (0.39%)
- Ex-Dividend Date Jun 19, 2024
- 1y Target Est
--
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. The company has collaboration with Belgium's Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
www.aftpharm.com110
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AFP.AX
View MorePerformance Overview: AFP.AX
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AFP.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AFP.AX
View MoreValuation Measures
Market Cap
250.45M
Enterprise Value
271.53M
Trailing P/E
24.81
Forward P/E
12.63
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.48
Price/Book (mrq)
3.47
Enterprise Value/Revenue
1.50
Enterprise Value/EBITDA
12.99
Financial Highlights
Profitability and Income Statement
Profit Margin
5.85%
Return on Assets (ttm)
7.82%
Return on Equity (ttm)
14.40%
Revenue (ttm)
198.51M
Net Income Avi to Common (ttm)
11.61M
Diluted EPS (ttm)
0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
10.69M
Total Debt/Equity (mrq)
40.27%
Levered Free Cash Flow (ttm)
3.43M